Application of lupenone in preparation of medicine for treating psoriasis
By increasing the number of CD4+Foxp3+Tregs cells in psoriasis patients through lupinone and regulating the immune response, the shortcomings of existing psoriasis treatments have been addressed, resulting in a significant reduction in skin lesion scores and improvement in skin condition.
Patent Information
- Application Number
- CN202411202009.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-29
Smart Images

Figure BDA0005018070380000031 
Figure HDA0005018070390000011 
Figure HDA0005018070390000012
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of pharmacology, and in particular to application of lupeolone in preparing a drug for treating psoriasis. Background Art
[0002] Psoriasis is an immune-mediated chronic inflammatory disease that is linked to T-cell-mediated immunity and inflammatory responses, and interacts with the pathogenesis of many major diseases, including arthritis, obesity-metabolic syndrome, cardiovascular disease, and malignant tumors (including kidney cancer, breast cancer, lung cancer, and colon cancer). Therefore, psoriasis brings serious psychological or physical burdens to patients. About 2% of the world's population suffers from psoriasis, which is the most common autoimmune skin disease in adults.
[0003] Existing studies have found that Foxp3 + The number of Treg cells increased, and its increase was positively correlated with the Psoriasis Activity and Severity Index (PASI). + CD25 + Foxp3 + Treg cells also appear in psoriasis lesions, and similar to peripheral blood, lesional biopsies are higher than control or healthy skin biopsies. These findings suggest that regulatory T cells (Tregs) play a role in the pathogenesis of psoriasis. However, how to inhibit the onset of psoriasis by regulating Treg cells has not yet been studied. Summary of the invention
[0004] According to one aspect of the present invention, there is provided use of lupetone in preparing a medicament for treating psoriasis.
[0005] The applicant of the present invention surprisingly found that lupinone has a significant therapeutic effect on psoriasis, can significantly reduce the severity of psoriasis, improve the erythema, scaling and infiltration of skin lesions, significantly reduce the PASI (psoriasis area and severity index) score of skin lesions, reduce the thickness of the epidermis at the lesions and inhibit epidermal hyperplasia, improve hyperkeratosis, parakeratosis, improve acanthosis, and improve weight loss. This is because lupinone can significantly induce regulatory T cells (Tregs, specifically CD4 + Foxp3 + The number of Tregs cells) increases, thereby regulating the immune effects in psoriasis patients and achieving the treatment of immune-mediated psoriasis.
[0006] In some embodiments, the above application is the application of lupine ketone in the preparation of a psoriasis drug having one or more of the following effects: improving the erythema, scaling and infiltration thickness of skin lesions; reducing the PASI score of skin lesions; reducing the epidermal thickness at the lesions and inhibiting epidermal hyperplasia; improving hyperkeratosis, parakeratosis, and acanthosis.
[0007] In some embodiments, the dosage of lupetin in the drug for treating psoriasis is 100 mg / kg body weight / day.
[0008] According to another aspect of the present invention, there is provided a use of lupine ketone in the preparation of a medicament for increasing the number of regulatory T lymphocytes in vivo.
[0009] In some embodiments, the above application is the application of lupine ketone in the preparation of a drug for increasing the number of regulatory T lymphocytes in the spleen and / or lymph nodes.
[0010] In some embodiments, the regulatory T lymphocytes are CD4 + Foxp3 + Tregs cells. Among them, CD4 + Foxp3 + Tregs cells are composed of CD4 + CD25 - Differentiated from T cells.
[0011] According to another aspect of the present invention, there is provided a use of lupeolone in the preparation of a medicament for reducing the positive expression of CD3 in psoriasis lesional tissues.
[0012] Compared with the prior art, the present invention has the following beneficial effects:
[0013] The present invention first discovered that lupine ketone has a significant therapeutic effect on imiquimod-induced psoriasis in mice. The present invention uses lupine ketone to treat psoriasis, which can upregulate CD4 + Foxp3 + The number of regulatory T lymphocytes, Tregs cells, reduces the positive expression of CD3 and the level of inflammatory factors in the skin lesions of patients with psoriasis, improves the infiltration of inflammatory cells in the skin tissue, regulates the immune effects of patients with psoriasis, and further achieves the treatment of psoriasis, significantly reduces the severity of psoriasis, reduces the PASI score of skin lesions and the thickness of the epidermis at the lesions, inhibits epidermal hyperplasia, and lupeolpe has the characteristics of low side effects and good safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 These are photos of skin lesions on the backs of mice in different groups in the experiment of the present invention.
[0015] Figure 2 It is the PASI score of mice in different groups in the experiment of the present invention.
[0016] Figure 3 It is HE staining of skin tissues of mice in different groups in the experiment of the present invention.
[0017] Figure 4 It is the immunohistochemical staining of the skin tissues of different groups of mice in the experiment of the present invention.
[0018] Figure 5 In the experiment of the present invention, ELISA was used to measure the cytokines IL-6, TNF-α, and IL-17A released from the skin tissues of mice in different groups.
[0019] Figure 6 The regulatory T lymphocytes (CD4 + Foxp3 + Flow cytometry density plot of Tregs.
[0020] Figure 7 The regulatory T lymphocytes (CD4 + Foxp3 + Tregs) are shown in the bar graph. DETAILED DESCRIPTION
[0021] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0022] If the specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments used without specifying the manufacturer are all conventional products that can be purchased commercially. The molecular formula of lupenone (CAS: 1617-70-5) used in the present invention is C 30 H 48 O, molecular weight: 424.7, structural formula:
[0023]
[0024] In order to verify the therapeutic effect of lupine ketone on psoriasis, the applicant constructed an imiquimod-induced mouse psoriasis model and conducted the following experiments. In the experiment, Mouse IL-6 ELISA Kit, Mouse TNF-α ELISA Kit, and Mouse IL-17A ELISA Kit (Wuhan Boster Biotechnology Co., Ltd.) were used to measure cytokines. Immunohistochemical staining was performed by conventional methods. Specifically, the primary antibody used Anti-CD3 (1:200, Abcam) and the secondary antibody used enzyme-labeled sheep anti-rabbit IgG polymer (Wuhan Boster Biotechnology Co., Ltd.).
[0025] 1. Animal Modeling and Drug Administration
[0026] 1. Construction of Psoriasis Mouse Model
[0027] Healthy 6-8 week old Balb / c male SPF mice were taken, and the dorsal hair of the mice was removed. The Balb / c mice were randomly divided into a normal control group (Ctrl), a model group (Vehicle) and a lupenone group (Lupenone). The depilatory areas of the mice in the model group and the lupenone group were coated with 5% (mass fraction) imiquimod (62.5 mg) (IMQ, Sichuan Mingxin Pharmaceutical Co., Ltd.) ointment for 7 days, with an area of about 3cm×3cm, once a day. On the third day after application, the mice began to show skin thickening and scaling. On the seventh day, scaling increased, skin thickening was obvious, and erythema was obvious. The psoriasis model was successfully established.
[0028] 2. Animal Dosage
[0029] The lupine ketone group was given lupine ketone (100 mg / kg / day) by gavage for 7 consecutive days starting from the first day, and the normal control group and the model group were given an equal amount of normal saline for 7 consecutive days.
[0030] The psoriasis mice treated with the above drugs were raised until the corresponding events, and then various psoriasis indicators were tested.
[0031] 2. Experimental Methods and Results
[0032] 1. Symptoms of skin lesions on the back
[0033] The skin lesions on the back of mice treated with different drugs were recorded and scored daily (erythema, scaling, infiltration and thickening level) (from mild to severe: 0-4 points), and the total score was obtained by adding the three scores. The PASI scoring standard is as follows: 0, none; 1, mild; 2, moderate; 3, severe; 4, very severe. Figure 1 , Figure 2 It can be seen that:
[0034] Compared with the back skin of mice in the normal group, the back skin of mice in the psoriasis model group was significantly thickened, and erythema and scaling appeared, similar to human psoriasis-like lesions, and the PASI score increased. Compared with the model group, the back skin of mice in the lupine ketone group was relieved after the application of lupine ketone, and the PASI score was reduced.
[0035] 2. Inflammatory cell infiltration
[0036] Cut the mouse lesion skin with an area of 0.5 cm × 0.5 cm to observe the skin damage. Perform HE staining for skin lesion histology. Figure 3 It can be seen that:
[0037] In HE staining, compared with the mice in the normal control group, the epidermal spinous cell layer of the mice in the psoriasis model group was significantly thickened, parakeratosis appeared in the stratum corneum, and there were residual condensed nuclei. A large number of inflammatory cell infiltrations were found in the dermis. The above symptoms were consistent with the histological characteristics of psoriasis-like lesions. Compared with the mice in the model group, the epidermal spinous cell layer of the mice in the lupine ketone group was significantly reduced, and the inflammatory cell infiltration in the dermis was reduced.
[0038] 3. Positive expression of CD3 in psoriasis lesions
[0039] The mouse lesion skin was cut to an area of 0.5 cm × 0.5 cm, and the skin damage was observed. Immunohistochemical staining of the lesion was performed. Figure 4 It can be seen that:
[0040] In immunohistochemical staining, the positive expression of CD3 in the epidermis and dermis of the skin lesions in the psoriasis model group increased significantly, while the positive expression of CD3 in the epidermis and dermis of the skin lesions in the lupine ketone group decreased significantly.
[0041] 4. Levels of inflammatory factors
[0042] Skin damage can also be determined by the production and secretion of cytokines IL-6, TNF-α, and IL-17A. Elisa was used to detect the release of these cytokines from the skin tissue of each group of mice. Figure 5 It can be seen that:
[0043] Compared with the control group, the levels of IL-6, TNF-α, and IL-17A in the skin lesions of mice in the model group were significantly upregulated (P<0.01). Compared with the model group, the levels of IL-6, TNF-α, and IL-17A in the skin lesions of mice in the lupine ketone group were significantly downregulated (P<0.01).
[0044] 5. CD4 in psoriasis mice + Foxp3 + The number of Tregs cells
[0045] Mice were treated with different drugs and fed for 1 week. The proportion of regulatory T cells in the spleen and lymph nodes of the mice was quantitatively analyzed by flow cytometry. Figures 6-7 It can be seen that:
[0046] CD4 in spleen and lymph nodes in the lupine group + Foxp3 + The proportions of Tregs cells were 6.43%±0.87% and 7.63%±0.97%, which were higher than those of the control group by 2.87%±0.95% (P<0.01) and 3.10%±0.76% (P<0.01), respectively.
[0047] The above results indicate that lupine ketone can significantly induce an increase in the number of regulatory T cells in the spleen and lymph nodes of mice, thereby regulating the immune effects of psoriasis mice.
[0048] The above five experiments and their results showed that lupine ketone can significantly improve the symptoms of psoriasis, reduce the PASI score of skin lesions, improve the infiltration of inflammatory cells in the skin, reduce the positive expression of CD3 and the level of inflammatory factors in the skin lesions of psoriasis models, and upregulate the expression of regulatory T lymphocytes (CD4 + Foxp3 + The proportion of Tregs.
[0049] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.
Claims
1. Application of lupine ketone in the preparation of drugs for the treatment of psoriasis.
2. The use according to claim 1, characterized in that: The application is the application of lupine ketone in the preparation of a psoriasis drug having one or more of the following effects: improving the erythema, scaling and infiltration thickness of skin lesions; reducing the PASI score of skin lesions; reducing the epidermal thickness at the lesion site and inhibiting epidermal hyperplasia; improving hyperkeratosis, parakeratosis, and acanthosis.
3. Application of lupine ketone in the preparation of drugs for increasing the number of regulatory T lymphocytes in the body.
4. The use according to claim 3, characterized in that: The application is the application of lupine ketone in the preparation of a medicine for increasing the number of regulatory T lymphocytes in the spleen and / or lymph nodes.
5. The use according to claim 3 or 4, characterized in that: The regulatory T lymphocytes are CD4 + Foxp3 + Tregs cells.
6. The use according to claim 5, characterized in that: The CD4 + Foxp3 + Tregs cells are composed of CD4 + CD25 - Differentiated from T cells.
7. Application of lupine ketone in the preparation of drugs for reducing CD3 positive expression in psoriasis lesional tissues.
Citation Information
Patent Citations
Application of lupenone to products for preventing or treating diabetes mellitus
CN102716135A
Application of lupenone in preparation of products for preventing and treating heart, liver and spleen injuries
CN115607554A
Application of lupenone in preparation of product for preventing and treating intestinal mucosal injury
CN117883452A
Pharmaceutical composition comprising triterpene compounds for prevention and treatment of bone diseases
KR1020130064662A
Teaching aid for improving creativity in mathematical science
KR1020240055355A
